Chemistry:Pibrentasvir
From HandWiki
Pibrentasvir is an NS5A inhibitor antiviral agent.[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.[2][3] It is sold by Abbvie.[citation needed]
ibrentasvir is a pangenotypic direct-acting antiviral that targets the hepatitis C virus (HCV) NS5A protein, which plays a key role in viral RNA replication and virion assembly.[4]. It is active against multiple HCV genotypes and has demonstrated high efficacy when used in combination with glecaprevir, contributing to sustained virologic response rates across diverse patient populations.[5]
References
- ↑ "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy 61 (5): e02558–16. May 2017. doi:10.1128/AAC.02558-16. PMID 28193664.
- ↑ "FDA OKs new drug to treat all forms of hepatitis C". Fox Business. August 3, 2017. http://www.foxbusiness.com/markets/2017/08/03/fda-oks-new-drug-to-treat-all-forms-hepatitis-c.html.
- ↑ "Maviret: EPAR – Summary for the public". European Medicines Agency. 2017-08-17. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004430/WC500233680.pdf.
- ↑ https://www.ema.europa.eu/es/documents/product-information/maviret-epar-product-information_es.pdf
- ↑ https://pmc.ncbi.nlm.nih.gov/articles/PMC11094641/
 |  |
